BA058-SC - Osteoporosis +
BA058 is a novel synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein), naturally-occuring bone building hormone. hPTHrP is a critical cytokine for the regulation of bone formation, able to build bone with low associated risk of inducing hypercalcemia as a side effect.
In a Phase 2 clinical trial, BA058 administered through a subcutaneous injection (BA058-SC) produced faster and greater bone mineral density increases at the spine and hip after six months and 12 months of treatment than did Forteo®, which was a comparator used in the study.
BA058-TD - Osteoporosis +
BA058-TD is a short wear-time transdermal form of BA058 based on 3M's patented Microstructured Transdermal System technology. The once-daily application of BA058-TD is expected to provide a more convenient treatment alternative to injection that may also improve treatment compliance among osteoporosis patients with convenience and ease of use.
In a series of phase 1 studies which showed the benefits of the short wear time patch, results demonstrated:
Radius commenced a Phase 2 clinical study for BA058-TD during the third quarter of 2012 and expects top-line data from this study to be available in the third quarter of 2013.
RAD1901 - Menopause+
RAD1901 is a selective estrogen receptor modulator (SERM) that is intended to treat vasomotor symptoms (hot flashes) in postmenopausal women. In preclinical studies, RAD1901 demonstrated the potential to reduce or prevent the hot flashes associated with menopause. In a four-week Phase 2a study, RAD1901 established clinical proof of concept, achieving a statistically significant reduction in frequency of moderate and severe hot flashes.